SLS is trading 4.7% up now at $13.90 after sharp swings over the past week, including a 24.7% jump on June 29 and a 10.1% drop on July 1. There are no fresh company-specific headlines or filings so far today, so the move appears to be part of ongoing biotech volatility and positioning ahead of key clinical trial outcomes rather than a new discrete event.